Athersys Inc. (ATHX) Stock Price Up 1.5%
Athersys Inc. (NASDAQ:ATHX) rose 1.5% on Tuesday . The stock traded as high as $2.04 and last traded at $2.00, with a volume of 280,389 shares changing hands. The stock had previously closed at $1.97.
ATHX has been the subject of several analyst reports. Zacks Investment Research raised shares of Athersys from a “hold” rating to a “buy” rating and set a $2.50 price target for the company in a research report on Monday, July 11th. Maxim Group reissued a “buy” rating on shares of Athersys in a research report on Monday, September 12th. Finally, TheStreet raised shares of Athersys from a “sell” rating to a “hold” rating in a research report on Tuesday, May 31st.
The company’s market capitalization is $168.26 million. The company has a 50 day moving average of $1.99 and a 200-day moving average of $2.19.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/athersys-inc-athx-stock-price-up-1-5.html
Athersys (NASDAQ:ATHX) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.02. Athersys had a negative net margin of 18.89% and a negative return on equity of 25.42%. The firm had revenue of $0.60 million for the quarter, compared to the consensus estimate of $0.32 million. During the same quarter in the previous year, the firm earned ($0.05) earnings per share. The company’s quarterly revenue was up 200.0% compared to the same quarter last year. Equities analysts predict that Athersys Inc. will post ($0.21) earnings per share for the current year.
In other news, EVP John J. Harrington sold 15,000 shares of the business’s stock in a transaction on Friday, September 16th. The shares were sold at an average price of $1.96, for a total value of $29,400.00. Following the transaction, the executive vice president now owns 619,639 shares of the company’s stock, valued at $1,214,492.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 10.90% of the stock is currently owned by insiders.
Several institutional investors have recently added to or reduced their stakes in ATHX. NEXT Financial Group Inc increased its position in Athersys by 1.4% in the second quarter. NEXT Financial Group Inc now owns 92,750 shares of the biopharmaceutical company’s stock valued at $201,000 after buying an additional 1,250 shares during the period. A.R.T. Advisors LLC boosted its stake in shares of Athersys by 2.5% in the second quarter. A.R.T. Advisors LLC now owns 69,953 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 1,715 shares in the last quarter. LPL Financial LLC boosted its stake in shares of Athersys by 30.8% in the first quarter. LPL Financial LLC now owns 51,000 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 12,000 shares in the last quarter. Alambic Investment Management L.P. boosted its stake in shares of Athersys by 164.3% in the second quarter. Alambic Investment Management L.P. now owns 56,300 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 35,000 shares in the last quarter. Finally, Nationwide Fund Advisors acquired a new stake in shares of Athersys during the second quarter valued at $104,000. 17.86% of the stock is currently owned by hedge funds and other institutional investors.
Athersys Company Profile
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.